Navigation Links
Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
Date:11/14/2007

Following the Screening and the Testing of Hundreds of MicroRNAs, Eight MicroRNAs Were Identified that Effectively Reduce Liver Cancer Cell Growth

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, November 14 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today the initiation of in vivo studies in its microRNA-based liver cancer therapeutic program conducted in collaboration with Isis Pharmaceuticals(1) (NASDAQ: ISIS). The project, combining Isis's extensive know how and IP in antisense chemistry and Rosetta Genomics' know how and proprietary microRNA platform technologies, is the companies' leading attempt at harnessing microRNAs' role as master switches of the human body to develop a treatment for cancer.

Out of hundreds of potential microRNAs screened and tested, eight have been identified to lead to a decrease in liver cancer cell growth when inhibited. These microRNAs will be further tested during the in vivo studies.

Liver cancer is the third most common cause of cancer deaths in men and the tenth most common in women, according to the National Cancer Institute. Approximately 20,000 people will die this year of liver cancer in the US alone.

"Rosetta and Isis decided two years ago to focus on developing a microRNA-based drug for this deadly cancer," noted Amir Avniel, CEO and President of Rosetta Genomics. "We are proud to present these results, demonstrating that microRNAs play a key role in liver cancer, and that targeting them in vitro leads to a decrease in cancer cell growth. We look forward to starting the in vivo studies."

Data on this program was presented by the two companies at the American Association for Cancer Research (AACR) conference; "The Rol
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
8. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
9. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
10. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
11. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... , Aug. 25, 2015   WuXi PharmaTech (Cayman) ... capability and technology platform company serving the pharmaceutical, biotechnology, ... ("Lee,s Pharm," Hong Kong Exchange Stock Code: 0950), a ... with 20 years of operations in ... companies have signed an agreement whereby WuXi,s Laboratory Testing ...
(Date:8/25/2015)... 2015 Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... joined the company as Chief Operating Officer. Winham, who brings ... technical experience, will report directly to HLI,s CEO, J. ... role as COO, Winham will be responsible for managing all ... all facility operations. HLI currently has three locations in ...
(Date:8/25/2015)... Aug. 25, 2015  InformedDNA, a leading provider ... has been awarded Certification in Utilization Management by ... NCQA is a private, non-profit organization ... a wide range of healthcare organizations. It also ... performance. "Our achievement of the NCQA ...
(Date:8/25/2015)... PRUSSIA, Pa. , Aug. 25, 2015   ... has been enrolled in its Phase II/III clinical study ... company,s recombinant fusion protein linking coagulation factor VIIa with ... hemophilia A or B who have developed an inhibitor ... study will enroll approximately 54 male patients, the first ...
Breaking Biology Technology:WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2InformedDNA Achieves NCQA Utilization Management Certification 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 3CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 4
... 100,000 doses can be manufactured per week , , ... that today it commenced manufacturing of a vaccine to protect ... estimates that it can produce 100,000 doses this week and ... called PanBlok(R), is made using PSC,s proprietary baculovirus and insect ...
... , SEATTLE, June 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. ... today announced the appointment of Scott Peterson, Ph.D., ... In this position, Dr. Peterson will be responsible ... development activities that will support the advancement of ...
... , SAN DIEGO, June 15 Hollis-Eden Pharmaceuticals, ... development of a new class of small molecule compounds based ... directors has appointed James M. Frincke Ph.D. as President and ... elected to the company,s board of directors. , , ...
Cached Biology Technology:Commercial Manufacturing of H1N1 'Swine Flu' Vaccine Underway 2Oncothyreon appoints Scott Peterson as Vice President of Research and Development 2Oncothyreon appoints Scott Peterson as Vice President of Research and Development 3Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO 2Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO 3
(Date:8/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... Smart Card Alliance and the EMV Migration Forum.  ... Smart Card Alliance Latin America (SCALA) Chapter provides NXT-ID, ... thought leaders promoting adoption of smart card technology. ...
(Date:8/18/2015)... DUBLIN , Aug. 17, 2015 ... the addition of the "Global Biometric Authentication ... Application - Estimation & Forecast, 2015-2020" report ... biometric authentication and identification systems market is expected ... from 2015 to 2020 and generate over $25 ...
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... sense of touch, researchers have shown. A study, by Dr ... at the University of Surrey, has found that Bacillus mycoides ... forces and curvature in the medium on which it,s growing. ... as revealed in the journal PLOS ONE , could signal ...
... in German . ... More precise tests may allow allergy sufferers more freedom of food ... out by the Helmholtz Centre for Environmental Research (UFZ), the University ... examined patients with a Nile perch allergy. Being allergic to Nile ...
... - December 10, 2013 Researchers at the Icahn ... strain of influenza the virus that causes the flu ... even after it develops resistance to antiviral medications. The finding was ... Nature Communications . It is not uncommon for ...
Cached Biology News:The garden microbe with a sense of touch 2Each food fish can cause specific allergies 2Each food fish can cause specific allergies 3Mount Sinai researchers say new strain of bird flu packs a punch even after becoming drug-resistant 2